Dr. Karen Fay Higgins, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1345 Whispering Pines Ln, Grass Valley, CA 95945 Phone: 530-274-9762 |
Dr. Peter James Vander Veer, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 500 Crown Point Cir, Suite 120, Grass Valley, CA 95945 Phone: 530-265-1437 |
Dr. Shari Crane Fox, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1350 E Main St, Grass Valley, CA 95945 Phone: 530-477-8545 |
Douglas Crisp, Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 500 Crown Point Cir, Suite 120, Grass Valley, CA 95945 Phone: 530-265-1437 |
Aubrey Lee Eubanks, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 500 Crown Point Cir Ste 120, Grass Valley, CA 95945 Phone: 530-265-1437 |
Dr. William Joseph Blaha, M.D. Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 152 Catherine Ln, Suite F, Grass Valley, CA 95945 Phone: 530-272-2858 Fax: 530-272-1832 |
Dr. Susan Ann Greenawald, M.D. Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 380 Sierra College Dr, Ste 200, Grass Valley, CA 95945 Phone: 530-477-6283 Fax: 530-477-1450 |
Dr. Fred R Moss, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 121 Stanford Ct, Grass Valley, CA 95945 Phone: 916-671-0007 |
News Archive
The Government of Quebec's Ministère de la santé et des services sociaux has approved the addition of Revlimid(R) (lenalidomide) to the Province's Drug Formulary as a third-line therapy for multiple myeloma patients. The cost of the drug will be reimbursed under the Province's medicare system.
Childhood bullying can lead to long term health consequences, including general and mental health issues, behavioral problems, eating disorders, smoking, alcohol use, and homelessness, a study by the Crime Victims' Institute at Sam Houston State University found.
CFO Harry Welten, MBA, commented: "Our cost-saving measures have been implemented, resulting in a substantial reduction of the cash burn. We expect to have cash and financial investments of around CHF 14 million at the end of 2009."
ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).
Certara, a leading provider of scientific software and consulting services to improve productivity and decision-making from drug discovery through drug development, announced that a Top 5 Pharma selected PKS Online as the platform of choice to support their regulatory compliant NCA analysis for clinical pharmacology.
› Verified 5 days ago